# ZEB1

Source: https://onco.cc/targets/zeb1/  
OnCo record `zeb1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ZEB1 (Zinc finger E-box-binding homeobox 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Nasopharyngeal carcinoma, Multiple myeloma and 4 more.

## Summary

Acts as a transcriptional repressor. Inhibits interleukin-2 (IL-2) gene expression. Enhances or represses the promoter activity of the ATP1A1 gene depending on the quantity of cDNA and on the cell type.

CIViC holds 9 clinical evidence items and 0 assertions across 3 variants, naming Doxorubicin, Salinomycin, Gemcitabine and Cytarabine and others. IntOGen calls it a driver in 6 cohorts (5 activating, 1 loss-of-function), covering Glioblastoma Multiforme, Lung Adenocarcinoma, Lung Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Plasma Cell Myeloma, Small Cell Lung Cancer.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: zinc finger E-box binding homeobox 1; Zinc finger E-box-binding homeobox 1; AREB6; NIL-2-A; Zfhep; Zfhx1a; FECD6; TCF8; PPCD3
- Tags: cancer-genes-wave
- Symbol: ZEB1
- Class: transcription
- Biology: Acts as a transcriptional repressor. Inhibits interleukin-2 (IL-2) gene expression. Enhances or represses the promoter activity of the ATP1A1 gene depending on the quantity of cDNA and on the cell type. Represses E-cadherin promoter and induces an epithelial-mesenchymal transition (EMT) by recruiting SMARCA4/BRG1. Represses BCL6 transcription in the presence of the corepressor CTBP1. Positively regulates neuronal differentiation. Location: Nucleus (UniProt). Locus 10p11.22 (HGNC).
- Where found: Colorectal cancer: CIViC evidence names this disease; Nasopharyngeal carcinoma: IntOGen driver in 1 cohort (NPC); Multiple myeloma: IntOGen driver in 1 cohort (PCM); Mantle cell lymphoma: CIViC evidence names this disease; Non-small-cell lung cancer: IntOGen driver in 2 cohorts (LUAD, LUSC); Glioma & glioblastoma: IntOGen driver in 1 cohort (GBM)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 7 therapies; IntOGen calls it an activating (Act) driver in 5 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 9 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:11642: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11642
- UniProt P37275: https://www.uniprot.org/uniprotkb/P37275/entry
- NCBI Gene 6935: https://www.ncbi.nlm.nih.gov/gene/6935
- Ensembl ENSG00000148516: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000148516

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/)
- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Nasopharyngeal carcinoma](https://onco.cc/cancers/nasopharyngeal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- pathways: [Epithelial-mesenchymal transition & drug efflux](https://onco.cc/pathways/emt/), [Invasion: proteases, adhesion & the invasive front](https://onco.cc/pathways/invasion-ecm-degradation/)

---
JSON: https://onco.cc/api/v1/entities/zeb1.json